| | References | Exclusion reason |
| | 1 | A. Ben Braiek, H. Chahed, F. Dumont, F. Abdelhak, D. Hichem, H. Gamra, and B. Baudin, “Identification of biomarker panels as predictors of severity in coronary artery disease,” Journal of Cellular and Molecular Medicine, vol. 25(3), pp. 1518-1530, 2021 | Not reporting MMP-2 | | 2 | A. A. Elhewala, M. Sanad, A. M. Soliman, M. A. Y. M. Sami, and A. A. Ahmed, “Matrix metalloproteinase-9 in pediatric rheumatic heart disease with and without heart failure,” Biomedical Reports, vol. 14(1), pp. 4, 2021 | Not reporting MMP-2 | | 3 | A. Gugerell, K. Zlabinger, D. Lukovic, J. Winkler, R. Hemetsberger, L. Mandic, D. Traxler, A. Spannbauer, N. Pavo, and M. Gyongyosi, “Effect of MMP-2 on compromised homing of intracoronary delivery of mesenchymal stem cell in a porcine reperfused myocardial infarction: comparison with intramyocardial cell delivery,” Cardiovascular Research, vol. 114 (1), pp. S28–S29, 2018. | An in vitro study | | 4 | A. J. Mouton, O. J. Rivera Gonzalez, A. R. Kaminski, E. T. Moore, and M. L. Lindsey, “Matrix metalloproteinase-12 as an endogenous resolution promoting factor following myocardial infarction,” Pharmacological Research, vol. 137, pp. 252-258, 2018. | A review article and not reporting MMP-2 | | 5 | A. Kubota, A. Suto, K. Suzuki, Y. Kobayashi, and H. Nakajima, “Matrix metalloproteinase-12 produced by Ly6Clow macrophages prolongs the survival after myocardial infarction by preventing neutrophil influx,” Journal of Molecular and Cellular Cardiology, vol. 131, pp. 41–52, 2019. | Not reporting MMP-2 | | 6 | A. Shevchenko, V. Prokofiev, V. Konenkov, and Y. Ragino, “Association of inflammation, destruction and angiogenesis genes polymorphism with serum levels of matrix metalloproteinases 3 and 9 in patients with coronary atherosclerosis,” Ural-Siberian Conference on Computational Technologies in Cognitive Science, Genomics and Biomedicine (CSGB), Novosibirsk, Russian Federation, pp. 290-294, 2022. | Not reporting MMP-2 | | 7 | C. A. Meschiari, M. Jung, R. P. Iyer, A. Yabluchanskiy, H. Toba, M. R. Garrett, and M. L. Lindsey, “Macrophage overexpression of matrix metalloproteinase-9 in aged mice improves diastolic physiology and cardiac wound healing after myocardial infarction. American Journal of Physiology,” Heart and Circulatory Physiology, vol. 314(2), pp. H224–H235, 2018. | Not reporting MMP-2 | | 8 | C. Guan, Y. Xiao, K. Li, T. Wang, Y. Liang, and G. Liao, “MMP-12 regulates proliferation of mouse macrophages via the ERK/P38 MAPK pathways during inflammation,” Experimental Cell Research, vol. 378(2), pp. 182-190, 2019. | An in vivo study and not reporting MMP-2 | | 9 | C. Wang, C. Song, Q. Liu, R. Zhang, R. Fu, H. Wang, D. Yin, W. Song, H. Zhang, and K. Dou, “Gene Expression Analysis Suggests Immunological Changes of Peripheral Blood Monocytes in the Progression of Patients With Coronary Artery Disease,” Frontiers in Genetics, vol.12, pp. 641117, 2021. | Not reporting MMP-2 | | 10 | D. Balakrishna, B. Sowjanya, M. Prasad, and R. Viswakumar, “Age- And Gender-Based Predisposition Of MMP-9 -1562 C > T Genotype And Allele Frequencies With Serum MMP-9 Levels As Probable Risk Factors In Patients With Coronary Artery Disease,” Indian Journal of Clinical Biochemistry, 2022. | Not reporting MMP-2 | | 11 | D. J. Medina-Leyte, O. Zepeda-García, M. Domínguez-Pérez, A. González-Garrido, T. Villarreal-Molina, and L. Jacobo-Albavera, “Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches,” International Journal of Molecular Sciences, vol. 22(8), pp. 3850, 2021. | A review article | | 12 | D. Opincariu, I. Rodean, N. Rat, R. Hodas, I. Benedek, and T. Benedek, “Systemic Vulnerability, as Expressed by I-CAM and MMP-9 at Presentation, Predicts One Year Outcomes in Patients with Acute Myocardial Infarction-Insights from the VIP Clinical Study,” Journal of Clinical Medicine, vol. 10(15), pp. 3435, 2021. | Not reporting MMP-2 | | 13 | D. Wang, X. Lou, X. M. Jiang, C. Yang, X. L. Liu, and N. Zhang, “Quercetin protects against inflammation, MMP-2 activation and apoptosis induction in rat model of cardiopulmonary resuscitation through modulating Bmi-1 expression,” Molecular Medicine Reports, vol. 18(1), pp. 610-616, 2018. | An in vivo study | | 14 | H. Funayama, T. Yoshioka, S. E. Ishikawa, S. I. Momomura, and K. Kario, “Close Association of Matrix Metalloproteinase-9 Levels With the Presence of Thin-Cap Fibroatheroma in Acute Coronary Syndrome Patients: Assessment by Optical Coherence Tomography and Intravascular Ultrasonography,” Cardiovascular Revascularization Medicine, vol. 32, pp. 5-10, 2021. | Not reporting MMP-2 | | 15 | G. Angelini, D. Flego, R. Vinci, D. Pedicino, F. Trotta, A. Ruggio, G. P. Piemontese, D. Galante, M. Ponzo, L. M. Biasucci, G. Liuzzo, and F. Crea, “Matrix metalloproteinase-9 might affect adaptive immunity in non-ST segment elevation acute coronary syndromes by increasing CD31 cleavage on CD4+ T-cells,” European Heart Journal, vol. 39(13), pp. 1089-1097, 2018 | Not reporting MMP-2 | | 16 | G. Kremastiotis, I. Handa, C. Jackson, S. George, and J. Johnson, “Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis,” Scientific Reports, vol. 11(1), pp. 23081, 2021. | Not reporting MMP-2 | | 17 | G. Sangeethadevi, S. U. V V, R. A. R. Jansy Isabella, G. Saravanan, P. Ponmurugan, P. Chandrasekaran, S. Sengottuvelu, and S. Vadivukkarasi, “Attenuation of lipid metabolic abnormalities, proinflammatory cytokines, and matrix metalloproteinase expression by biochanin-A in isoproterenol-induced myocardial infarction in rats,” Drug and Chemical Toxicology, vol. 45(5), pp. 1951-1962, 2022. | An in vivo study | | 18 | G. Simões, T. Pereira, A. Caseiro, G. Simoes, T. Pereira, and A. Caseiro, “Matrix metalloproteinases in vascular pathology,” Microvascular Research, vol. 143, pp. 104398, 2022. | A review article | | 19 | H. F. Ebrahim, F. F. Abdel Hamid, M. A. Haykal, and A. F. Soliman, “Cyclophilin A and matrix metalloproteinase-9: Their relationship, association with, and diagnostic relevance in stable coronary artery disease”, Vascular, vol. 28(2), pp. 212-221, 2020. | Not reporting MMP-2 | | 20 | I. Guizani, W. Zidi, Y. Zayani, F. Nesrine, H. Douik, H. Sanhaji, M. S, Mourali, M. Feki, and M. Allal-Elasmi, “Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study,” Molecular Biology Reports, vol. 49(10), pp. 9171-9179, 2022. | Not reporting MMP-2 | | 21 | J. M. Howes, N. Pugh, S. W. Hamaia, S. M. Jung, V. Knäuper, J. D. Malcor, R. W. Farndale, “MMP-13 binds to platelet receptors αIIbβ3 and GPVI and impairs aggregation and thrombus formation,” Research & Practice in Thrombosis & Haemostasis, vol. 2(2), pp. 370-379, 2018. | Not reporting MMP-2 | | 22 | J. Nordeng, H. Schandiz, S. Solheim, S. Åkra, P. Hoffman, B. Roald, B. Bendz, H. Arnesen, R. Helseth, and I. Seljeflot, “TIMP-1 expression in coronary thrombi associate with myocardial injury in ST-elevation myocardial infarction patients. Coronary Artery Disease, vol. 33(6), pp. 446-455, 2022. | Not reporting MMP-2 | | 23 | K. Brassington, S. Selemidis, S. Bozinovski, and R. Vlahos, “Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics,” Clinical Science, vol. 136(6), pp. 405-423, 2022. | A review article | | 24 | K. Pahk, C. Joung, H. Y. Song, S. Kim, and W. Kim, “A Novel Cd147 Inhibitor Sp-8356 Attenuates Plaque Progression And Stabilizes Vulnerable Plaque In Apoe-Deficient Mice,” Journal of Hypertension, vol. 37, pp. e105–e106, 2019. | An in vivo study | | 25 | L. Li, J. Li, J. Yi, H. Liu, and H. Lei, “Dose-Effect of Irbesartan on Cyclooxygenase-2 and Matrix Metalloproteinase-9 Expression in Rabbit Atherosclerosis,” Journal of Cardiovascular Pharmacology, vol. 71(2), pp. 82-94, 2018. | An in vivo study and not reporting MMP-2 | | 26 | L. Yang, H. G. Sui, M. M, Wang, J. Y. Li, X. F. He, J. Y. Li, and X. Z. Wang, “MiR-30c-1-3p targets matrix metalloproteinase 9 involved in the rupture of abdominal aortic aneurysms,” Journal of Molecular Medicine, vol. 100(8), pp. 1209-1221, 2022. | Not reporting MMP-2 | | 27 | L. Schirone, M. Forte, L. D’Ambrosio, V. Valenti, D. Vecchio, S. Schiavon, G. Spinosa, G. Sarto, V. Petrozza, G. Frati, and S. Sciarretta, “An Overview of the Molecular Mechanisms Associated with Myocardial Ischemic Injury: State of the Art and Translational Perspectives,” Cells, vol. 11(7), pp. 1165, 2022. | A review article | | 28 | M. K. Georgakis, S. W. Van Der Laan, Y. Asare, J. M. Mekke, S, Haitjema, A. H. Schoneveld, S. C. A. De Jager, N. S. Nurmohamed, J. Kroon, E. S. G. Stroes, D. P. V. De Kleijn, G. J. De Borst, L. Maegdefessel, O. Soehnlein, G. Pasterkamp, and M. Dichgans, “Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate with Plaque Vulnerability,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 41 (6), pp. 2038-2048, 2021. | Not reporting relation with MMP-2 and/or CAD | | 29 | M. Medhet, W. El-Bakly, A. Badr, A. Awad, and E. El-Demerdash, “Thymoquinone attenuates isoproterenol-induced myocardial infarction by inhibiting cytochrome C and matrix metalloproteinase-9 expression,” Clinical and Experimental Pharmacology and Physiology, vol. 49 (3), pp. 391-405, 2022. | Not reporting MMP-2 | | 30 | M. Kumric, J. A. Borovac, D. Martinovic, T. Ticinovic Kurir, and J. Bozic, “Circulating Biomarkers Reflecting Destabilization Mechanisms of Coronary Artery Plaques: Are We Looking for the Impossible?,” Biomolecules, vol. 11(6), pp. 881, 2021. | A review article | | 31 | M. Sabry, S. Mostafa, L. Rashed, M. Abdelgwad, S. Kamar, and S. Estaphan, “Matrix metalloproteinase 9 a potential major player connecting atherosclerosis and osteoporosis in high fat diet fed rats,” PLOS ONE, vol. 16(2), 2021. | An in vivo study | | 32 | M. Sheikhvatan, M. A. Boroumand, M. Behmanesh, and S. Ziaee, “Association of R279Q and C1562T polymorphisms of matrix metalloproteinase 9 gene and increased risk for myocardial infarction in patients with premature coronary artery disease,” Journal of Clinical Laboratory Analysis, vol. 32(1), 2018. | Not reporting MMP-2 | | 33 | M. Skrzypiec-Spring, J. Urbaniak, A. Sapa-Wojciechowska, A. Pietkiewicz, A. Orda, B. Karolko, R. Danielewicz, I. Bil-Lula, M. Woźniak, R. Schulz, and A. Szeląg, “Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injury-Cardioprotective Properties of Carvedilol,” Pharmaceuticals (Basel), vo. 14(12), pp. 1276, 2021. | An in vivo study | | 34 | M. U. Somuncu, H. Pusuroglu, H. Karakurt, I. I. Bolat, S. T. Karakurt, A. R. Demir, N. Isiksacan, O. Akgul, O. Surgit, N. Isıksacan, O. Akgul, and O. Surgit, “The prognostic value of elevated matrix metalloproteinase-9 in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: A two-year prospective study,” Revista Portuguesa de Cardiologia, vol. 39(5), pp. 267–276, 2020. | Not reporting MMP-2 | | 35 | M. M Zhang, X. W. Chang, X. Q. Hao, H. Wang, X. Xie, and S. Y. Zhang, “Association between matrix metalloproteinase 9 C-1562T polymorphism and the risk of coronary artery disease: an update systematic review and meta-analysis,” Oncotarget, vol. 9(10), pp. 9468–9479, 2018. | Not reporting MMP-2 | | 36 | N. Malkani, M. Farheen, H. Hamid, A. Batool, R. U. Khan, and A. Yaqub, “Matrix metalloprotease-9 polymorphism and its association with Atherosclerosis—A case-control study in Pakistani population,” Journal of Pakistan Medical Association, vol. 69(10), pp. 1416-1420, 2019. | Not reporting MMP-2 | | 37 | P. R. Gonçalves, L. D. Nascimento, R. F. Gerlach, K. E. Rodrigues, and A. F. Prado, “Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure,” Pharmaceuticals (Basel), vol. 15(8), pp. 920, 2022. | A review article | | 38 | P. Libby, J. E. Buring, L. Badimon, G. K. Hansson, J. Deanfield, M. S. Bittencourt, L. Tokgözoğlu, and E. F. Lewis, “Atherosclerosis,” Nature Reviews Disease Primers, vol. 5(1), 2019. | A review article | | 39 | P. Theofilis, M. Sagris, A. S. Antonopoulos, E. Oikonomou, K. Tsioufis, and D. Tousoulis, “Non-Invasive Modalities in the Assessment of Vulnerable Coronary Atherosclerotic Plaques,” Tomography, vol. 8(4), pp.1742-1758, 2022. | A review article | | 40 | R. Hassanzadeh-Makoui, B. Razi, S. Aslani, D. Imani, and S. S. Tabaee, “The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronary Artery Disease (CAD): a systematic review and meta-analysis,” BMC Cardiovascular Disorders, vol. 20(1), pp. 232, 2020. | A systematic review and meta-analysis article | | 41 | R. Huang, Y. Xin, R. Zhu, J. Song, M. Luo, and D. A. Chen, “Meta-Analysis of Matrix Metalloproteinases in the Risk of Cardiovascular and Neurodegenerative Diseases,” BioMed Research International, vol. 2022, pp. 3360316, 2022. | A systematic review and meta-analysis article | | 42 | S. Iwańczyk, T. Lehmann, M. Grygier, P. Woźniak, M. Lesiak, and A. Araszkiewicz, “Serum matrix metalloproteinase-8 level in patients with coronary artery abnormal dilatation,” Polish Archives of Internal Medicine, vol. 132(5), pp. 16241, 2022. | Not reporting MMP-2 | | 43 | S. J. George, and J. L. Johnson, “Investigation of Atherosclerotic Plaque Vulnerability,” Methods in Molecular Biology, vol. 2419, pp. 521-535, 2022. | Book chapters | | 44 | S. Jebari-Benslaiman, U. Galicia-García, A. Larrea-Sebal, J. R. Olaetxea, I. Alloza, K. Vandenbroeck, A. Benito-Vicente, and C. Martín, “Pathophysiology of Atherosclerosis,” International Journal of Molecular Sciences, vol. 23(6), pp. 3346, 2022. | Not reporting relation with MMP-2 and/or CAD | | 45 | S. Shi, and J. L.Yi, “S100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα,” European Review for Medical and Pharmacological Sciences, vol. 22(12), pp. 3925-3935, 2018. | Not reporting MMP-2 | | 46 | S. Zhang, Y. Liu, Y. Cao, S. Zhang, J. Sun, Y. Wang, S. Song, H. Zhang, “Targeting the Microenvironment of Vulnerable Atherosclerotic Plaques: An Emerging Diagnosis and Therapy Strategy for Atherosclerosis,” Advanced Materials, vol. 34 (29), 2022. | A review article | | 47 | T. Radhiga, S. Senthil, A. Sundaresan, and K. V. Pugalendi. “Ursolic acid modulates MMPs, collagen-I, α-SMA, and TGF-β expression in isoproterenol-induced myocardial infarction in rats,” Human & Experimental Toxicology, vol. 38(7):785-793, 2019. | An in vivo study | | 48 | V. Lubrano, and S. Balzan, “Status of biomarkers for the identification of stable or vulnerable plaques in atherosclerosis,” Clinical Science, vol. 135(16), pp. 1981-1997, 2021. | A review article | | 49 | W. Gong, Y. Ma, A. Li, H. Shi, and S. Nie, “Trimetazidine suppresses oxidative stress, inhibits MMP-2 and MMP-9 expression, and prevents cardiac rupture in mice with myocardial infarction,” Cardiovascular Therapeutics, vol. 36(5), pp. e12460, 2018. | An in vivo study | | 50 | W. Hu, R. Wei, L. Wang, J. Lu, H. Liu, and W. Zhang, “Correlations of MMP-1, MMP-3, and MMP-12 with the degree of atherosclerosis, plaque stability and cardiovascular and cerebrovascular events,” Experimental and Therapeutic Medicine, vol. 15(2), pp. 1994-1998, 2018. | Not reporting MMP-2 | | 51 | W. Wu, D. Liu, S. Jiang, K. Zhang, H. Zhou, and Q. Lu. “Polymorphisms in gene MMP-2 modify the association of cadmium exposure with hypertension risk,” Environment International, vol. 124, pp. 441-447, 2019. | Not reporting relations with atherosclerosis and/or CAD | | 52 | X. Qiao, S. Bhave, L. Swain, E. Zweck, L. Reyelt, P. Crowley, S. K. Annamalai, A. Chennjorwala, M. Esposito, A. Razavi, S. Foroutanjazi, C. Machen, K. Thayer, L. Korde, R. H. Karas, and N. K. Kapur, “Myocardial Injury Promotes Matrix Metalloproteinase-9 Activity in the Renal Cortex in Preclinical Models of Acute Myocardial Infarction,” Journal of Cardiovascular Translational Research, vol. 15(2), pp. 207–216, 2022. | Not reporting MMP-2 | | 53 | Y. Chen, A. B. Waqar, K. Nishijima, B. Ning, S. Kitajima, F. Matsuhisa, L. Chen, E. Liu, T. Koike, Y. Yu, J. Zhang, Y. E. Chen, H. Sun, J. Liang, and J. Fan. “Macrophage-derived MMP-9 enhances the progression of atherosclerotic lesions and vascular calcification in transgenic rabbits,” Journal of Cellular and Molecular Medicine, vol. 24(7), pp. 4261-4274, 2020. | Not reporting MMP-2 | | 54 | Y. Hu, X. Dong, T. Zhang, H. Ma, W. Yang, Y. Wang, P. Liu, and Y. Chen. “Kai-Xin-San suppresses matrix metalloproteinases and myocardial apoptosis in rats with myocardial infarction and depression,” Molecular Medicine Reports, vol. 21(1), pp. 508-516, 2020. | An in vivo study | | 55 | Y. S. Ma, Y. H. Xie, D. Ma, J. J. Zhang, and H. J. Liu, “Shear stress-induced MMP1 and PDE2A expressions in coronary atherosclerosis,” Bratislava Medical Journal, vol. 122(4), pp. 287-292, 2021. | Not reporting MMP-2 | | 56 | Y. Yang, G. Li, and R. Zhang, “Correlation Analysis of Acute Coronary Syndrome with Serum IL-18, MMP-9, hs-CRP, and Plasma FIB,” BioMed Research International, vol. 2022, pp. 5984184, 2022. | Not reporting MMP-2 |
|
|
